What is Agios Pharmaceuticals Inc's earnings per share (EPS)?

Agios Pharmaceuticals Inc (AGIO) reported diluted earnings per share of $-7.12 for fiscal year 2025. This represents a -161.2% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Agios Pharmaceuticals Inc Financials

AGIO

Source SEC Filings (10-K/10-Q) Updated Mar 31, 2026 Currency USD FYE December

This page shows Agios Pharmaceuticals Inc (AGIO) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI AGIO FY2025 2026-04-29

Agios remains a balance-sheet-funded R&D business, with revenue scale still far too small to absorb roughly $375M of annual cash burn.

Between FY2024 and FY2025, net income swung from $674M to -$413M, yet operating cash outflow barely changed from -$390M to -$373M. That mismatch means the FY2024 profit was not evidence of a self-funding operating model: even with FY2025 revenue up to $54M, free cash flow was still -$377M.

FY2025 looked conservatively financed despite the burn: current assets were $942M against only $82M of current liabilities, and total liabilities were just $104M on $1.3B of assets. The interesting detail is that cash itself was only $89M, so much of the liquidity cushion appears to sit outside plain cash balances.

The cost structure still reflects development intensity: FY2025 R&D of $340M plus SG&A of $180M outweighed revenue of $54M by almost 10x. Revenue has climbed from $27M in FY2023, but the expense base has risen too, so higher sales have not yet translated into lower cash consumption or operating losses.

Financial Health Signals

Financial Profile 50/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Agios Pharmaceuticals Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Agios Pharmaceuticals Inc has an operating margin of -873.9%, meaning the company retains $-874 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -1166.5% the prior year.

Growth

100

Agios Pharmaceuticals Inc's revenue surged 48.0% year-over-year to $54.0M, reflecting rapid business expansion. This strong growth earns a score of 100/100.

Leverage

100

Agios Pharmaceuticals Inc carries a low D/E ratio of 0.09, meaning only $0.09 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

100

With a current ratio of 11.46, Agios Pharmaceuticals Inc holds $11.46 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.

Cash Flow

While Agios Pharmaceuticals Inc generated -$373.0M in operating cash flow, capex of $4.3M consumed most of it, leaving -$377.3M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.

Returns

Agios Pharmaceuticals Inc generates a -34.6% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is down from 43.7% the prior year.

Piotroski F-Score Weak

2/9

Agios Pharmaceuticals Inc passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 efficiency signals pass.

Earnings Quality Low Quality

0.90x

For every $1 of reported earnings, Agios Pharmaceuticals Inc generates $0.90 in operating cash flow (-$373.0M OCF vs -$413.0M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$54.0M

YoY+48.0%

10Y CAGR-0.9%

Agios Pharmaceuticals Inc generated $54.0M in revenue in fiscal year 2025. This represents an increase of 48.0% from the prior year.

EBITDA

-$466.9M

YoY-11.2%

Agios Pharmaceuticals Inc's EBITDA was -$466.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 11.2% from the prior year.

Net Income

-$413.0M

YoY-161.3%

Agios Pharmaceuticals Inc reported -$413.0M in net income in fiscal year 2025. This represents a decrease of 161.3% from the prior year.

EPS (Diluted)

$-7.12

YoY-161.2%

Agios Pharmaceuticals Inc earned $-7.12 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 161.2% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$377.3M

YoY+3.6%

Agios Pharmaceuticals Inc generated -$377.3M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 3.6% from the prior year.

Cash & Debt

$89.1M

YoY+16.9%

5Y CAGR-6.9%

10Y CAGR+2.2%

Agios Pharmaceuticals Inc held $89.1M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

59M

YoY+2.3%

5Y CAGR-3.3%

10Y CAGR+4.5%

Agios Pharmaceuticals Inc had 59M shares outstanding in fiscal year 2025. This represents an increase of 2.3% from the prior year.

Margins & Returns

Gross Margin

88.3%

YoY-0.3pp

Agios Pharmaceuticals Inc's gross margin was 88.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 0.3 percentage points from the prior year.

Operating Margin

-873.9%

YoY+292.6pp

10Y CAGR-673.1pp

Agios Pharmaceuticals Inc's operating margin was -873.9% in fiscal year 2025, reflecting core business profitability. This is up 292.6 percentage points from the prior year.

Net Margin

-764.4%

YoY-2611.1pp

10Y CAGR-565.3pp

Agios Pharmaceuticals Inc's net profit margin was -764.4% in fiscal year 2025, showing the share of revenue converted to profit. This is down 2611.1 percentage points from the prior year.

Return on Equity

-34.6%

YoY-78.4pp

5Y CAGR+47.3pp

10Y CAGR-0.5pp

Agios Pharmaceuticals Inc's ROE was -34.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 78.4 percentage points from the prior year.

Capital Allocation

R&D Spending

$339.5M

YoY+12.7%

5Y CAGR+9.0%

10Y CAGR+9.1%

Agios Pharmaceuticals Inc invested $339.5M in research and development in fiscal year 2025. This represents an increase of 12.7% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$4.3M

YoY+156.1%

5Y CAGR-21.1%

10Y CAGR-14.3%

Agios Pharmaceuticals Inc invested $4.3M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 156.1% from the prior year.

AGIO Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$54.0M+48.0%	$36.5M+36.1%	$26.8M+88.4%	$14.2M	$0	$0
Cost of Revenue	$6.3M+52.3%	$4.2M+44.6%	$2.9M+69.1%	$1.7M	$0	$0
Gross Profit	$47.7M+47.5%	$32.3M+35.0%	$23.9M+91.0%	$12.5M	$0	$0
R&D Expenses	$339.5M+12.7%	$301.3M+1.9%	$295.5M+5.6%	$279.9M+8.9%	$257.0M+16.4%	$220.8M
SG&A Expenses	$180.3M+15.0%	$156.8M+30.8%	$119.9M-1.5%	$121.7M+0.2%	$121.4M+5.5%	$115.1M
Operating Income	-$472.1M-10.9%	-$425.7M-8.7%	-$391.5M-0.6%	-$389.0M-2.8%	-$378.4M-12.7%	-$335.9M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	-$1.0M-102.3%	$44.2M	$0	$0	N/A	N/A
Net Income	-$413.0M-161.3%	$674.0M+291.5%	-$352.0M-51.7%	-$232.0M-114.5%	$1.6B+590.3%	-$327.4M
EPS (Diluted)	$-7.12-161.2%	$11.64+283.9%	$-6.33-49.6%	$-4.23-115.9%	$26.55+660.1%	$-4.74

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	$20.7M+3.9%	$20.0M+55.0%	$12.9M+3.4%	$12.5M+42.7%	$8.7M-18.7%	$10.7M+19.7%	$9.0M+4.1%	$8.6M
Cost of Revenue	$1.3M-29.8%	$1.9M+11.9%	$1.7M-1.4%	$1.7M+56.9%	$1.1M-13.9%	$1.3M+60.9%	$783K-47.6%	$1.5M
Gross Profit	$19.4M+7.4%	$18.1M+61.5%	$11.2M+4.2%	$10.8M+40.7%	$7.6M-19.3%	$9.5M+15.8%	$8.2M+14.9%	$7.1M
R&D Expenses	$81.1M-7.8%	$88.1M+1.5%	$86.8M-5.6%	$91.9M+26.4%	$72.7M-12.2%	$82.8M+14.3%	$72.5M-6.4%	$77.4M
SG&A Expenses	$48.3M-6.4%	$51.6M+25.0%	$41.3M-10.0%	$45.9M+10.5%	$41.5M-19.7%	$51.7M+34.1%	$38.5M+8.4%	$35.5M
Operating Income	-$110.0M+9.5%	-$121.6M-4.0%	-$116.9M+8.0%	-$127.1M-19.2%	-$106.6M+14.7%	-$125.0M-21.6%	-$102.8M+2.8%	-$105.8M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	$0	N/A	N/A	N/A	$53.1M	N/A
Net Income	-$99.1M+8.4%	-$108.3M-4.7%	-$103.4M+7.7%	-$112.0M-25.5%	-$89.3M+7.2%	-$96.2M-110.2%	$947.9M+1086.2%	-$96.1M
EPS (Diluted)	$-1.69	N/A	$-1.78+7.8%	$-1.93-24.5%	$-1.55	N/A	$16.22+1059.8%	$-1.69

AGIO Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$1.3B-22.0%	$1.7B+77.5%	$937.1M-24.3%	$1.2B-13.8%	$1.4B+68.6%	$853.0M
Current Assets	$942.1M-2.4%	$965.6M+15.8%	$833.8M+0.1%	$832.8M-21.7%	$1.1B+67.2%	$636.7M
Cash & Equivalents	$89.1M+16.9%	$76.2M-13.6%	$88.2M-36.7%	$139.3M-31.4%	$203.1M+59.4%	$127.4M
Inventory	$32.9M+19.2%	$27.6M+44.8%	$19.1M+124.6%	$8.5M	$0-100.0%	$14.7M
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$104.1M-14.8%	$122.2M-3.1%	$126.1M-8.6%	$137.9M-5.4%	$145.8M-67.9%	$453.5M
Current Liabilities	$82.2M+1.3%	$81.2M+19.4%	$68.0M+8.5%	$62.6M+4.7%	$59.8M-36.6%	$94.4M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$1.2B-22.6%	$1.5B+90.0%	$811.0M-26.3%	$1.1B-14.8%	$1.3B+223.4%	$399.5M
Retained Earnings	-$561.7M-277.2%	-$148.9M+81.9%	-$822.6M-74.8%	-$470.6M-97.1%	-$238.8M+87.0%	-$1.8B

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$1.2B-8.7%	$1.3B-6.4%	$1.4B-5.8%	$1.5B-5.4%	$1.6B-6.5%	$1.7B-7.2%	$1.8B+131.8%	$773.1M
Current Assets	$834.8M-11.4%	$942.1M-8.8%	$1.0B+1.3%	$1.0B+5.2%	$968.6M+0.3%	$965.6M-10.1%	$1.1B+69.9%	$632.1M
Cash & Equivalents	$113.6M+27.5%	$89.1M-3.9%	$92.7M+14.6%	$80.9M+2.4%	$79.0M+3.6%	$76.2M-69.9%	$253.7M+200.2%	$84.5M
Inventory	$35.1M+6.6%	$32.9M+2.8%	$32.0M+3.8%	$30.8M+4.2%	$29.6M+7.2%	$27.6M+4.5%	$26.4M+10.4%	$23.9M
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$75.9M-27.1%	$104.1M+2.7%	$101.4M-0.3%	$101.7M+14.3%	$89.0M-27.2%	$122.2M-26.0%	$165.1M+46.7%	$112.6M
Current Liabilities	$58.8M-28.4%	$82.2M+10.0%	$74.8M+6.2%	$70.4M+34.5%	$52.4M-35.5%	$81.2M-32.1%	$119.5M+90.7%	$62.6M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$1.1B-7.0%	$1.2B-7.1%	$1.3B-6.2%	$1.4B-6.6%	$1.5B-4.8%	$1.5B-5.3%	$1.6B+146.3%	$660.5M
Retained Earnings	-$660.8M-17.6%	-$561.7M-23.8%	-$453.7M-29.5%	-$350.2M-47.0%	-$238.2M-60.0%	-$148.9M-184.2%	-$52.4M+94.8%	-$1.0B

AGIO Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$373.0M+4.3%	-$389.8M-31.7%	-$296.1M+4.3%	-$309.5M+24.0%	-$407.3M-40.1%	-$290.8M
Capital Expenditures	$4.3M+156.1%	$1.7M+68.7%	$999K-79.5%	$4.9M-15.0%	$5.7M-59.3%	$14.1M
Free Cash Flow	-$377.3M+3.6%	-$391.5M-31.8%	-$297.1M+5.5%	-$314.4M+23.9%	-$413.1M-35.5%	-$304.9M
Investing Cash Flow	$377.2M+3.8%	$363.4M+51.7%	$239.6M-1.5%	$243.3M-80.5%	$1.2B+1548.6%	$75.7M
Financing Cash Flow	$8.7M-39.9%	$14.4M+165.8%	$5.4M+131.2%	$2.4M+100.3%	-$765.8M-392.8%	$261.5M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	$0	$0-100.0%	$802.5M	$0

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$118.9M-23.6%	-$96.2M-9.1%	-$88.2M-14.3%	-$77.1M+30.8%	-$111.5M+16.3%	-$133.2M-58.1%	-$84.2M-16.0%	-$72.6M
Capital Expenditures	$769K-31.3%	$1.1M-28.0%	$1.6M+77.7%	$875K+14.2%	$766K-20.8%	$967K+130.8%	$419K+165.2%	$158K
Free Cash Flow	-$119.7M-23.0%	-$97.3M-8.5%	-$89.7M-15.0%	-$78.0M+30.5%	-$112.3M+16.3%	-$134.1M-58.5%	-$84.6M-16.3%	-$72.7M
Investing Cash Flow	$141.3M+56.9%	$90.1M-5.7%	$95.6M+21.0%	$79.0M-29.9%	$112.6M+329.0%	-$49.2M-119.6%	$250.8M+573.4%	$37.2M
Financing Cash Flow	$2.1M-18.7%	$2.6M-42.3%	$4.4M+6723.1%	$65K-96.0%	$1.6M-66.6%	$4.8M+83.6%	$2.6M+139.9%	$1.1M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

AGIO Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	88.3%-0.3pp	88.6%-0.7pp	89.3%+1.2pp	88.0%	N/A	N/A
Operating Margin	-873.9%+292.6pp	-1166.5%+293.1pp	-1459.5%+1272.5pp	-2732.1%	N/A	N/A
Net Margin	-764.4%-2611.1pp	1846.7%+3159.0pp	-1312.3%+316.9pp	-1629.2%	N/A	N/A
Return on Equity	-34.6%-78.4pp	43.7%+87.1pp	-43.4%-22.3pp	-21.1%-145.3pp	124.2%+206.2pp	-81.9%
Return on Assets	-31.8%-72.4pp	40.5%+78.1pp	-37.6%-18.8pp	-18.7%-130.4pp	111.6%+150.0pp	-38.4%
Current Ratio	11.46-0.4	11.90-0.4	12.27-1.0	13.30-4.5	17.79+11.0	6.74
Debt-to-Equity	0.090.0	0.08-0.1	0.16+0.0	0.13+0.0	0.11-1.0	1.14
FCF Margin	-698.3%+374.4pp	-1072.7%+34.8pp	-1107.5%+1100.1pp	-2207.6%	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	93.6%+3.0pp	90.6%+3.6pp	87.0%+0.6pp	86.3%-1.2pp	87.6%-0.7pp	88.3%-3.0pp	91.3%+8.6pp	82.7%
Operating Margin	-530.3%+78.5pp	-608.9%+298.5pp	-907.4%+112.7pp	-1020.1%+201.8pp	-1222.0%-56.7pp	-1165.3%-18.4pp	-1146.9%+81.4pp	-1228.3%
Net Margin	-477.7%+64.4pp	-542.2%+260.9pp	-803.0%+96.3pp	-899.4%+123.9pp	-1023.3%-126.2pp	-897.0%-11471.7pp	10574.7%+11690.4pp	-1115.7%
Return on Equity	-8.9%+0.1pp	-9.1%-1.0pp	-8.1%+0.1pp	-8.2%-2.1pp	-6.1%+0.2pp	-6.2%-64.5pp	58.3%+72.8pp	-14.5%
Return on Assets	-8.4%0.0pp	-8.3%-0.9pp	-7.5%+0.2pp	-7.6%-1.9pp	-5.7%+0.1pp	-5.8%-58.7pp	52.9%+65.3pp	-12.4%
Current Ratio	14.19+2.7	11.46-2.4	13.82-0.7	14.48-4.0	18.50+6.6	11.90+2.9	8.99-1.1	10.09
Debt-to-Equity	0.07-0.0	0.090.0	0.080.0	0.07+0.0	0.06-0.0	0.08-0.0	0.10-0.1	0.17
FCF Margin	-576.9%-89.5pp	-487.5%+209.0pp	-696.5%-70.2pp	-626.3%+660.2pp	-1286.4%-36.4pp	-1250.1%-305.9pp	-944.2%-99.8pp	-844.4%

Similar Companies

Travere Therapeutics Inc TVTX

$4.0B

Denali Therapeut DNLI

$3.0B

Disc Medicine Inc IRON

$2.6B

Apogee Therapeutics Inc APGE

$6.1B

Frequently Asked Questions

What is Agios Pharmaceuticals Inc's annual revenue?

Agios Pharmaceuticals Inc (AGIO) reported $54.0M in total revenue for fiscal year 2025. This represents a 48.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Agios Pharmaceuticals Inc's revenue growing?

Agios Pharmaceuticals Inc (AGIO) revenue grew by 48% year-over-year, from $36.5M to $54.0M in fiscal year 2025.

Is Agios Pharmaceuticals Inc profitable?

No, Agios Pharmaceuticals Inc (AGIO) reported a net income of -$413.0M in fiscal year 2025, with a net profit margin of -764.4%.

What is Agios Pharmaceuticals Inc's EBITDA?

Agios Pharmaceuticals Inc (AGIO) had EBITDA of -$466.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Agios Pharmaceuticals Inc's gross margin?

Agios Pharmaceuticals Inc (AGIO) had a gross margin of 88.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Agios Pharmaceuticals Inc's operating margin?

Agios Pharmaceuticals Inc (AGIO) had an operating margin of -873.9% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Agios Pharmaceuticals Inc's net profit margin?

Agios Pharmaceuticals Inc (AGIO) had a net profit margin of -764.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Agios Pharmaceuticals Inc's return on equity (ROE)?

Agios Pharmaceuticals Inc (AGIO) has a return on equity of -34.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Agios Pharmaceuticals Inc's free cash flow?

Agios Pharmaceuticals Inc (AGIO) generated -$377.3M in free cash flow during fiscal year 2025. This represents a 3.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Agios Pharmaceuticals Inc's operating cash flow?

Agios Pharmaceuticals Inc (AGIO) generated -$373.0M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Agios Pharmaceuticals Inc's total assets?

Agios Pharmaceuticals Inc (AGIO) had $1.3B in total assets as of fiscal year 2025, including both current and long-term assets.

What are Agios Pharmaceuticals Inc's capital expenditures?

Agios Pharmaceuticals Inc (AGIO) invested $4.3M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Agios Pharmaceuticals Inc spend on research and development?

Agios Pharmaceuticals Inc (AGIO) invested $339.5M in research and development during fiscal year 2025.

How many shares does Agios Pharmaceuticals Inc have outstanding?

Agios Pharmaceuticals Inc (AGIO) had 59M shares outstanding as of fiscal year 2025.

What is Agios Pharmaceuticals Inc's current ratio?

Agios Pharmaceuticals Inc (AGIO) had a current ratio of 11.46 as of fiscal year 2025, which is generally considered healthy.

What is Agios Pharmaceuticals Inc's debt-to-equity ratio?

Agios Pharmaceuticals Inc (AGIO) had a debt-to-equity ratio of 0.09 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Agios Pharmaceuticals Inc's return on assets (ROA)?

Agios Pharmaceuticals Inc (AGIO) had a return on assets of -31.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Agios Pharmaceuticals Inc's cash runway?

Based on fiscal year 2025 data, Agios Pharmaceuticals Inc (AGIO) had $89.1M in cash against an annual operating cash burn of $373.0M. This gives an estimated cash runway of approximately 3 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Agios Pharmaceuticals Inc's Piotroski F-Score?

Agios Pharmaceuticals Inc (AGIO) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Agios Pharmaceuticals Inc's earnings high quality?

Agios Pharmaceuticals Inc (AGIO) has an earnings quality ratio of 0.90x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Agios Pharmaceuticals Inc?

Agios Pharmaceuticals Inc (AGIO) scores 50 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.